Can you provide the average price target for KORRO BIO INC stock?
16 analysts have analysed KRRO and the average price target is 20.15 USD. This implies a price increase of 56.28% is expected in the next year compared to the current price of 12.89.
KORRO BIO INC (KRRO) Forecast, Price Target & Analyst Ratings
NASDAQ:KRRO • US5009461089
Current stock price
12.89 USD
-0.7 (-5.19%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KORRO BIO INC (KRRO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.88
- Revenue Estimate
- 625.668K
Price Target Details & History
Consensus Price Target and Range
Mean target
$20.15
Upside
+ 56.28%
From current price of $12.89 to mean target of $20.15, Based on 16 analyst forecasts
Low
$8.08
Median
$21.42
High
$31.50
Price Target Revisions
1 Month
3.17%
3 Months
-56.11%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for KRRO. The average price target is 20.15 USD. This implies a price increase of 56.28% is expected in the next year compared to the current price of 12.89.
The average price target has been revised downward by 56.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
KRRO was analyzed by 16 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about KRRO.
In the previous month the buy percentage consensus was at a similar level.
KRRO was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-03-13 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2026-02-19 | Clear Street | Upgrade | Hold -> Buy |
| 2026-02-17 | William Blair | Upgrade | Market Perform -> Outperform |
| 2026-01-29 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2026-01-29 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2026-01-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2026-01-28 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2026-01-28 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-11-14 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-11-13 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-11-13 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-11-13 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-11-13 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-31 | Clear Street | Initiate | Buy |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-13 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-16 | Chardan Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.88
- Revenue Estimate
- 625.668K
- Revenue Q2Q
- -75.46%
- EPS Q2Q
- 24.54%
- Number of Analysts
- 10
Next Earnings Revisions
Revenue (1 Month)
26.91%
Revenue (3 Months)
28.68%
EPS (1 Month)
-3.07%
EPS (3 Months)
7.64%
Next Earnings Summary
KRRO is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -1.88 USD and the consensus revenue estimate is 625.67K USD.
The next earnings revenue estimate has been revised upward by 28.68% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.271M | 6.392M 181.46% | 2.503M -60.84% | 909.585K -63.66% | -100.00% | 2.355M | 34.406M 1,360.98% | 111.1M 222.91% | 259.58M 133.65% | 503.53M 93.98% | ||
| EBITDA YoY % growth | -80.904M -43.23% | -88.345M -9.20% | -83.062M 5.98% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -84.534M -43.28% | -91.91M -8.73% | -87.342M 4.97% | -77.708M 11.03% | -92.144M -18.58% | -107.712M -16.90% | -192.658M -78.86% | -232.731M -20.80% | -206.947M 11.08% | -96.876M 53.19% | 25.463M 126.28% | |
| Operating Margin | N/A | -4,047.12% | -1,366.43% | -3,104.58% | -10,130.31% | N/A | -8,180.79% | -676.42% | -186.27% | -37.32% | 5.06% | |
| EPS YoY % growth | -83.65 27.89% | -9.39 88.77% | -8.80 6.28% | -6.70 23.85% | -6.95 -3.71% | -7.73 -11.21% | -11.15 -44.27% | -13.71 -22.96% | -13.00 5.21% | -6.09 53.11% | 1.24 120.42% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.88 24.54% | -1.63 40.56% | -1.85 3.67% | -2.00 -21.37% | -1.61 14.50% | -1.65 -1.46% | -1.69 8.46% | -1.74 13.16% |
| Revenue Q2Q % growth | 625.668K -75.46% | 591.6K -59.48% | 591.6K -45.72% | 591.6K -54.21% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.191M 19.30% | -21.008M 22.77% | -21.159M -9.99% | -23.764M -49.62% | -25.033M -23.98% | -27.108M -29.03% | -29.367M -38.79% | -31.83M -33.94% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
3.90%
EPS Next 5 Year
-9.27%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
43.85%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
KORRO BIO INC / KRRO Forecast FAQ
Can you provide the upcoming earnings date for KORRO BIO INC?
KORRO BIO INC (KRRO) will report earnings on 2026-05-05.
What are the consensus estimates for KORRO BIO INC (KRRO) next earnings?
The consensus EPS estimate for the next earnings of KORRO BIO INC (KRRO) is -1.88 USD and the consensus revenue estimate is 625.67K USD.
Can you provide the consensus rating for KORRO BIO INC stock?
The consensus rating for KORRO BIO INC (KRRO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.